MX2023001532A - Agonistas del receptor npy2 solubles. - Google Patents

Agonistas del receptor npy2 solubles.

Info

Publication number
MX2023001532A
MX2023001532A MX2023001532A MX2023001532A MX2023001532A MX 2023001532 A MX2023001532 A MX 2023001532A MX 2023001532 A MX2023001532 A MX 2023001532A MX 2023001532 A MX2023001532 A MX 2023001532A MX 2023001532 A MX2023001532 A MX 2023001532A
Authority
MX
Mexico
Prior art keywords
soluble
receptor agonists
analogues
npy2 receptor
relates
Prior art date
Application number
MX2023001532A
Other languages
English (en)
Inventor
Stefan Peters
Albert Brennauer
Charlotte Stahl Madsen
Søren Ljungberg Pedersen
Peter Haebel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2023001532A publication Critical patent/MX2023001532A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos de la invención son solubles a alrededor de pH 6 y 7. La invención también se refiere a composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos.
MX2023001532A 2020-08-07 2021-08-05 Agonistas del receptor npy2 solubles. MX2023001532A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20189966 2020-08-07
PCT/EP2021/071873 WO2022029231A1 (en) 2020-08-07 2021-08-05 Soluble npy2 receptor agonists

Publications (1)

Publication Number Publication Date
MX2023001532A true MX2023001532A (es) 2023-03-08

Family

ID=71995807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001532A MX2023001532A (es) 2020-08-07 2021-08-05 Agonistas del receptor npy2 solubles.

Country Status (19)

Country Link
US (1) US20220041678A1 (es)
EP (1) EP4192853A1 (es)
JP (1) JP2023537036A (es)
KR (1) KR20230045088A (es)
CN (1) CN116171282A (es)
AR (1) AR123174A1 (es)
AU (1) AU2021322137A1 (es)
BR (1) BR112022025623A2 (es)
CA (1) CA3185637A1 (es)
CL (1) CL2023000357A1 (es)
CO (1) CO2023000637A2 (es)
CR (1) CR20230074A (es)
DO (1) DOP2023000010A (es)
EC (1) ECSP23003649A (es)
IL (1) IL300239A (es)
MX (1) MX2023001532A (es)
PE (1) PE20231566A1 (es)
TW (1) TW202222335A (es)
WO (1) WO2022029231A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4281464A1 (en) 2021-01-20 2023-11-29 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548978A (en) 2004-02-11 2009-10-30 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
NZ555533A (en) 2004-12-13 2010-03-26 Amylin Pharmaceuticals Inc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
AU2007360979B2 (en) 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
MX2011006313A (es) 2008-12-15 2011-09-27 Zealand Pharma As Analogos de glucagon.
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
DK2370460T3 (da) 2008-12-15 2014-08-04 Zealand Pharma As Glucagon analoger
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
CN102573888A (zh) 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
US8722849B2 (en) 2011-06-10 2014-05-13 Novo Nordisk A/S Polypeptides
CN104144696A (zh) 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014178018A1 (en) 2013-05-02 2014-11-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
KR102569036B1 (ko) 2013-10-17 2023-08-23 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
RS58530B1 (sr) 2013-11-14 2019-04-30 Keybioscience Ag Mimetici kalcitonina za lečenje bolesti i poremećaja
EP3068421B1 (en) 2013-11-15 2019-04-17 Novo Nordisk A/S Selective pyy compounds and uses thereof
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
RU2735762C2 (ru) 2015-04-16 2020-11-06 Зилэнд Фарма А/С Ацилированный аналог глюкагона, его применение и способы получения
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CR20220206A (es) * 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2

Also Published As

Publication number Publication date
JP2023537036A (ja) 2023-08-30
AR123174A1 (es) 2022-11-02
CA3185637A1 (en) 2022-02-10
CL2023000357A1 (es) 2023-09-29
WO2022029231A1 (en) 2022-02-10
ECSP23003649A (es) 2023-03-31
CO2023000637A2 (es) 2023-01-26
PE20231566A1 (es) 2023-10-04
CR20230074A (es) 2023-04-19
TW202222335A (zh) 2022-06-16
KR20230045088A (ko) 2023-04-04
AU2021322137A1 (en) 2023-01-19
CN116171282A (zh) 2023-05-26
EP4192853A1 (en) 2023-06-14
IL300239A (en) 2023-03-01
DOP2023000010A (es) 2023-02-15
BR112022025623A2 (pt) 2023-03-07
US20220041678A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
CR20230074A (es) Agonistas del receptor npy2 solubles
MX2022005661A (es) Agonistas del receptor npy2.
PH12015501579B1 (en) Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
PH12018502465A1 (en) Mic-1 compounds and use thereof
PH12019550241A1 (en) Mic-1 compounds and uses thereof
EP2496245A4 (en) ANALOG OF PITUTIC ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHOD OF USE THEREOF
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
NZ743489A (en) Controlled-release cnp agonists with low npr-c binding
CR20210192A (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2022001719A (es) Formulaciones de conjugados de benzazepina y usos de las mismas.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MX2022008748A (es) Administración oral de péptidos.
BR112022006297A2 (pt) Agonistas de receptor de npy2
CR20220591A (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
MX2019010360A (es) Peptido modificado de helicobacter pylori para inducir inmunogenicidad contra infecciones ocasionadas por h. pylori.
RS20170169A1 (sr) Poboljšana rekonstituisana kompozicija sufraktanta koja sadrži analoge sufraktanta proteina b (sp-b) i surfaktanta proteina c (sp-c)
AR063251A1 (es) Compuesto peptidico pegilado composicion farmaceutica que lo comprende y su uso para fabricacion de un medicamento